Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells

Stem Cells

Volumn 28, Issue 11, 2010, Pages 1930-1939

  Sunayama, Jun ^a,c,d   Matsuda, Ken Ichiro ^a   Sato, Atsushi ^a   Tachibana, Ken ^a   Suzuki, Kaori ^b   Narita, Yoshitaka ^b   Shibui, Soichiro ^b   Sakurada, Kaori ^a   Kayama, Takamasa ^a   Tomiyama, Arata ^a   Kitanaka, Chifumi ^a,c,d  

^a YAMAGATA UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c YAMAGATA UNIVERSITY   (Japan)

^d JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

Author keywords

ERK; Glioblastoma stem cells; mTOR; p70S6K; PI3K

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE; PROTEIN P70 S6 KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER STEM CELL; CARCINOGENICITY; CELL DIFFERENTIATION; CELL LINEAGE; CELL RENEWAL; CONTROLLED STUDY; ENZYME INACTIVATION; ENZYME REGULATION; GLIA CELL; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; SIGNAL TRANSDUCTION;

AMINOACETONITRILE; ANIMALS; BUTADIENES; CELL DIFFERENTIATION; CELL LINE, TUMOR; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLIOBLASTOMA; HUMANS; IMIDAZOLES; MALE; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASTIC STEM CELLS; NITRILES; PHOSPHATIDYLINOSITOL 3-KINASES; QUINOLINES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

MAMMALIA;

EID: 78649831949     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.521     Document Type: Article

References (46)

1. Louis DN, Ohgaki H, Wiestler OD et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109.
2. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996.
3. Park DM, Rich JN. Biology of glioma cancer stem cells. Mol Cells 2009;28:7-12.
4. Liu G, Yuan X, Zeng Z et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006;5:67-78.
5. Blazek ER, Foutch JL, Maki G. Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys 2007;67:1-5. (Pubitemid 44959518)
6. Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest 2010;120:41-50.
7. Piccirillo SG, Reynolds BA, Zanetti N et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006;444:761-765.
8. Lee J, Son MJ, Woolard K et al. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 2008;13:69-80.
9. Ikushima H, Todo T, Ino Y et al. Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell 2009;5:504-514.
10. Penuelas S, Anido J, Prieto-Sanchez RM et al. TGF-beta increases glioma- initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 2009;15:315-327.
11. Wurdak H, Zhu S, Romero A et al. An RNAi screen identifies TRRAP as a regulator of brain tumor-initiating cell differentiation. Cell Stem Cell 2010;6:37-47.
12. Soni D, King JA, Kaye AH et al. Genetics of glioblastoma multiforme: mitogenic signaling and cell cycle pathways converge. J Clin Neurosci 2005;12:1-5.
13. Reardon DA, Rich JN, Friedman HS et al. Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 2006;24:1253-1265. (Pubitemid 46622028)
14. Wong AJ, Bigner SH, Bigner DD et al. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 1987;84:6899-6903.
15. Fleming TP, Saxena A, Clark WC et al. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 1992;52: 4550-4553.
16. Wong AJ, Ruppert JM, Bigner SH et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 1992;89:2965-2969.
17. Morrison RS, Yamaguchi F, Saya H et al. Basic fibroblast growth factor and fibroblast growth factor receptor I are implicated in the growth of human astrocytomas. J Neurooncol 1994;18:207-216. (Pubitemid 24209422)
18. Mizoguchi M, Betensky RA, Batchelor TT et al. Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: Correlation With EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol 2006;65:1181-1188.
19. Lopez-Gines C, Gil-Benso R, Benito R et al. The activation of ERK1/ 2 MAP kinases in glioblastoma pathobiology and its relationship with EGFR amplification. Neuropathology 2008;28:507-515.
20. Haas-Kogan D, Shalev N, Wong M et al. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol 1998;8:1195-1198.
21. Holland EC, Celestino J, Dai C et al. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 2000;25:55-57.
22. Wang SI, Puc J, Li J et al. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 1997;57:4183-4186.
23. Sabatini DM. mTOR and cancer: Insights into a complex relationship. Nat Rev Cancer 2006;6:729-734.
24. Sathornsumetee S, Rich JN. Designer therapies for glioblastoma multiforme. Ann N Y Acad Sci 2008;1142:108-132.
25. Marumoto T, Tashiro A, Friedmann-Morvinski D et al. Development of a novel mouse glioma model using lentiviral vectors. Nat Med 2009;15:110-116.
26. Lyustikman Y, Momota H, Pao W et al. Constitutive activation of Raf-1 induces glioma formation in mice. Neoplasia 2008;10:501-510.
27. Hu X, Pandolfi PP, Li Y et al. mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia 2005;7:356-368. (Pubitemid 40664225)
28. Fael Al-Mayhani TM, Ball SL, Zhao JW et al. An efficient method for derivation and propagation of glioblastoma cell lines that conserves the molecular profile of their original tumours. J Neurosci Methods 2009;176:192-199.
29. Pollard SM, Yoshikawa K, Clarke ID et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 2009;4: 568-580.
30. Nishida E, Gotoh Y. The MAP kinase cascade is essential for diverse signal transduction pathways. Trends Biochem Sci 1993;18:128-131. (Pubitemid 23105313)
31. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001;410:37-40.
32. Carracedo A, Ma L, Teruya-Feldstein J et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008;118:3065-3074.
33. Kinkade CW, Castillo-Martin M, Puzio-Kuter A et al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 2008;118: 3051-3064.
34. Ma L, Chen Z, Erdjument-Bromage H et al. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005;121:179-193.
35. Harrington LS, Findlay GM, Gray A et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 2004;166:213-223.
36. Tremblay F, Brule S, Hee Um S et al. Identification of IRS-1 Ser- 1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. Proc Natl Acad Sci USA 2007;104:14056-14061.
37. Um SH, Frigerio F, Watanabe M et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 2004;431:200-205.
38. Al-Hajj M, Becker MW, Wicha M et al. Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 2004;14:43-47.
39. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med 2006;355:1253-1261.
40. Maher EA, Furnari FB, Bachoo RM et al. Malignant glioma: Genetics and biology of a grave matter. Genes Dev 2001;15:1311-1333.
41. Furnari FB, Fenton T, Bachoo RM et al. Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Genes Dev 2007;21: 2683-2710.
42. Sunayama J, Sato A, Matsuda K, et al. Dual blocking of mTor and PI3K elicits a pro-differentiation effect on glioblastoma stem like-cells. Neuro Oncol 2010 epub ahead of print.
43. Houillier C, Lejeune J, Benouaich-Amiel A et al. Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer 2006;106:2218-2223.
44. Ohgaki H, Dessen P, Jourde B et al. Genetic pathways to glioblastoma: A population-based study. Cancer Res 2004;64:6892-6899.
45. Zheng H, Ying H, Yan H et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 2008; 455:1129-1133.
46. Julien LA, Carriere A, Moreau J et al. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol 2010;30:908-921.